Atlas Trials

Efficacy and Safety of Olokizumab in Patients With Progressive Fibrosing Interstitial Lung Diseases

Clinical trial NCT06440746 · RECRUITING

Trial details

NCT number
NCT06440746
Sponsor
R-Pharm International, LLC
Status
RECRUITING
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Lung Diseases, Interstitial
Start date
2023-08-23
Primary completion
2027-04-09
Enrollment
138

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.